Currently, there are 39.61M common shares owned by the public and among those 38.60M shares have been available to trade.
The company’s stock has a 5-day price change of -11.72% and 1.80% over the past three months. ANGO shares are trading -27.93% year to date (YTD), with the 12-month market performance down to -49.01% lower. It has a 12-month low price of $5.26 and touched a high of $11.38 over the same period. ANGO has an average intraday trading volume of 507.28K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.28%, -9.08%, and -12.72% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Angiodynamic Inc (NASDAQ: ANGO) shares accounts for 88.93% of the company’s 39.61M shares outstanding.
It has a market capitalization of $226.28M and a beta (3y monthly) value of 0.66. The earnings-per-share (ttm) stands at -$4.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.86% over the week and 4.56% over the month.
Earnings per share for the fiscal year are expected to decrease by -783.33%, and 6.60% over the next financial year.
Looking at the support for the ANGO, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on April 05, 2024, with the firm’s price target at $12. H.C. Wainwright coverage for the Angiodynamic Inc (ANGO) stock in a research note released on September 25, 2023 offered a Buy rating with a price target of $19. Raymond James was of a view on April 17, 2023 that the stock is Outperform, while Canaccord Genuity gave the stock Buy rating on October 15, 2021, issuing a price target of $28- $37. Oppenheimer on their part issued Perform rating on August 20, 2021.
